Definitions
Sorry, no definitions found. You may find more data at node-positive.
Etymologies
Sorry, no etymologies found.
Support
Help support Wordnik (and make this page ad-free) by adopting the word Node-Positive.
Examples
-
NeuVax(TM) (E75) makes significant progress towards initiating the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) Treatment) study in 1H, 2012
unknown title 2011
-
Based on a successful Phase 2 trial, which achieved its primary endpoint of disease free survival (DFS), the Food and Drug Administration (FDA) granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study.
unknown title 2011
-
Based on a successful Phase 2 trial, which achieved its primary endpoint of disease-free survival, the FDA granted NeuVax a Special Protocol Assessment for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) Treatment) study.
unknown title 2011
-
Galena will focus its resources on its lead product, NeuVax(TM), a cancer immunotherapy that is expected to initiate its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study in the first half of 2012.
unknown title 2011
-
PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study in the first half of 2012 under a Special Protocol Assessment (SPA).
unknown title 2011
-
The company expects to initiate its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax(TM) Treatment) study in the first half of 2012 under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA).
unknown title 2011
-
Oncotype DX Reduces Use of Chemotherapy in Treatment of Lymph Node-Negative and Lymph Node-Positive Breast Cancer Patients in
unknown title 2011
-
Genomic Health Announces Publication of Study Using Oncotype DX (R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
WN.com - Articles related to In memory of Mother: Why are vitamin supplements important part two 2010
-
Genomic Health Announces Results of Clinical Survey Showing Use of Oncotype DX (R) Changes Treatment Recommendations for Women With Lymph Node-Positive Breast Cancer, Leading to Overall Reduction in Chemotherapy
WN.com - Articles related to In memory of Mother: Why are vitamin supplements important part two 2010
-
Genomic Health Announces Publication of Study Using Oncotype DX (R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
Comments
Log in or sign up to get involved in the conversation. It's quick and easy.